NCT05041348 is a clinical trial of CT at the level of the third lumbar vertebra (L3) in Sarcopenia, sponsored by The Affiliated Hospital of Qingdao University.

Who is sponsoring NCT05041348?

NCT05041348 is sponsored by The Affiliated Hospital of Qingdao University.

What drugs are being tested in NCT05041348?

Interventions in NCT05041348: CT at the level of the third lumbar vertebra (L3).

What condition does NCT05041348 study?

NCT05041348 studies Sarcopenia.

Is NCT05041348 still recruiting?

NCT05041348 is currently completed. Last updated 15 September 2022.

Last reviewed 2022-09-15 · How we verify

NCT05041348

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metabonomic of Patients With Hepatitis B Cirrhosis Complicated With Sarcopenia.

Completed Last updated 15 September 2022

What this trial tests

trial testing CT at the level of the third lumbar vertebra (L3) in Sarcopenia in 60 participants. Completed in 17 August 2022.

Timeline

17 August 2021

Primary endpoint
15 July 2022

17 August 2022

Quick facts

Lead sponsor	The Affiliated Hospital of Qingdao University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	60
Start date	17 August 2021
Primary completion	15 July 2022
Estimated completion	17 August 2022
Sites	1 location across China

Drugs / interventions tested

CT at the level of the third lumbar vertebra (L3)

Conditions studied

Sarcopenia — all drugs for Sarcopenia →

Sponsor

The Affiliated Hospital of Qingdao University

Who can join

Adults 18 to 60, any sex, with Sarcopenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Sarcopenia is a common complication in liver cirrhosis patients and has been confirmed that associated with poor prognosis. China has the world's largest burden of hepatitis B virus-related liver cirrhosis (HBV-related liver cirrhosis). However, the relationship between HBV-related liver cirrhosis patients with muscle mass loss and normal muscle mass is remain largely unknown. Our study aimed to reveal the metabolic profile and identify potential biomarkers of muscle mass loss in HBV-related liver cirrhosis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Differential metabolites in cirrhotic patients with hepatitis B and muscle mass loss.
Liu X, Han L, Bi S, Ding X, et al · · 2023 · cited 4× · PMID 36875836 · DOI 10.3389/fnut.2023.1068779

Verify or expand the search:

Other recruiting trials for Sarcopenia

Currently open trials in the same condition.

NCT07500376 — Multimodal Nutritional and Sarcopenia Assessment for Risk Stratification in Lung Cancer Surgery · recruiting
NCT07456956 — HIIT vs MCIT for Stroke-Related Sarcopenia in Ischemic Stroke · NA · recruiting
NCT07398495 — Multimodal Training Effects in Middle-Aged and Older Adults With Diabetic Sarcopenia · NA · recruiting
NCT07494916 — Effects of Functional Task Training on Muscle Health and Function in Older Adults With Sarcopenia · NA · active not recruiting
NCT07426159 — AI-Guided Sarcopenia Risk Assessment and Detection · NA · active not recruiting

Other The Affiliated Hospital of Qingdao University trials

Trials by the same sponsor.

NCT07485920 — A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedani · Phase 4 · not yet recruiting
NCT07465861 — Bed Rest Duration and Outcomes in Endoscopic Skull Base Reconstruction · NA · not yet recruiting
NCT07453771 — Safety and Efficacy of Small Extracellular Vesicles Nebulizer in Patients With Allergic Rhinitis Complicated With Asthma · NA · not yet recruiting
NCT07404709 — Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Ste · Phase 1, PHASE2 · not yet recruiting
NCT07167342 — The Effect of Oral Clostridium Butyricum on the Recurrence After Colonoscopic Resection of Colorectal Adenoma · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05041348 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Affiliated Hospital of Qingdao University
Last refreshed: 15 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05041348.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing